Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence

Hemophilia therapies have tremendously improved over the last decades with the development of prolonged half-life factor VIII (FVIII) and FIX concentrates, non-factor therapies, such as emicizumab, anti-TFPI antibodies or siRNA antithrombin and gene therapy. All of these new molecules significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: Dargaud, Yesim, Janbain, Maissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665845/
https://www.ncbi.nlm.nih.gov/pubmed/34908888
http://dx.doi.org/10.2147/JBM.S260923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665845/
https://www.ncbi.nlm.nih.gov/pubmed/34908888
http://dx.doi.org/10.2147/JBM.S260923

Ejemplares similares